Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
NCT ID: NCT00555828
Last Updated: 2010-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
25 participants
INTERVENTIONAL
2008-03-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SecondaryObjective
The secondary objectives are to explore functional efficacy for subsequent study design, as well as late-term dose related tolerance, by:
* Evaluating the effect of allogeneic MPCs on exploratory efficacy endpoints related to cardiac function on Days 90, 180, and 1 year
* Evaluating the change from baseline in the Medical Outcome Study Short Form (SF-36), Kansas City Cardiomyopathy Questionnaire, Seattle Angina Questionnaire, and the New York Heart Association Classification at 30 days, 3 and 6 months, and 1, 2, and 3 years
* Evaluating follow-up safety through Day 360
* Providing preliminary data to support dose selection for future studies
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.
NCT02503280
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
NCT00721045
Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells
NCT05925608
To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction
NCT00526253
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
NCT01781390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A1
5 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection
Allogeneic Mesenchymal Precursor Cells (MPCs)
25 M allogeneic MPCs by transendocardial injection
A2
5 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
B1
5 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection
Allogeneic Mesenchymal Precursor Cells (MPCs)
75 M allogeneic MPCs by transendocardial injection
B2
3 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
C1
5 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection
Allogeneic Mesenchymal Precursor Cells (MPCs)
150 M allogeneic MPCs by transendocardial injection
C2
2 subjects randomized to receive standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Allogeneic Mesenchymal Precursor Cells (MPCs)
25 M allogeneic MPCs by transendocardial injection
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Allogeneic Mesenchymal Precursor Cells (MPCs)
75 M allogeneic MPCs by transendocardial injection
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Allogeneic Mesenchymal Precursor Cells (MPCs)
150 M allogeneic MPCs by transendocardial injection
Standard-of-care treatment with NOGA® mapping and staged injections.
Standard-of-care treatment with NOGA® mapping and staged injections.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. An ST-elevation MI (STEMI) within 2 to 10 days of study enrollment. The STEMI must be documented by ECG with ST-segment elevation \>1 mm in at least 2 contiguous precordial leads or in at least 2 adjacent limb leads. If there is a history of a previous AMI prior to the qualifying MI, then there must be a documented EF ≥ 50% by 2D echocardiogram within 12 months of enrollment.
3. Successful percutaneous revascularization with Thrombolysis in Myocardial Infarction (TIMI)-3 flow of the infarct-related artery.
4. A baseline 2D echocardiogram with EF ≥ 30 and ≤ 50% following PCI.
5. Creatinine level ≤ 1.5mg/dL within 24 hours of study procedure.
6. Hematocrit ≥ 30% within 24 hours of study procedure.
7. White Blood Cell count \< 20k/mm3 within 24 hours of study procedure.
8. Platelet count ≥ 100k/mm3 within 24 hours of study procedure.
9. INR ≤ 1.7 within 24 hours of study procedure.
10. Total bilirubin \<3 mg/dL, albumin \>2.8 g/dL, aspartate aminotransferase(AST) ≤ 2.5x the upper limit of normal, gamma glutamyltranspeptidase (GGT) ≤ 1.5 x the upper limit of normal.
11. If the subject or partner is of childbearing potential, he or she must be willing to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening and for a period of at least 16 weeks after surgery.
12. Female subjects of childbearing potential must have a negative serum pregnancy test at screening (within 2 weeks of enrollment) and a negative serum or urine pregnancy test on the day of cell implantation.
13. Willing and able to understand, sign, and date the Informed Consent Form (ICF).
14. Must be willing to return for required follow-up visits.
15. Must be able to follow postoperative management program.
Exclusion Criteria
1. Killip Class 4 indicative of cardiogenic shock.
2. Requirement of intra-aortic balloon pump or IV inotropic support for the maintenance of mean arterial blood pressure ≥ 60 mmHg.
2. Sustained ventricular tachycardia as demonstrated by QRS complexes wider than 120 msec, lasting \>30 secs, and \>100 bpm occurring \>48 hours following PCI without any identifiable, reversible cause (ie, electrolyte imbalance).
3. Further revascularization planned for the next 30 days.
4. Chronic atrial fibrillation.
5. A wall thickness in the target region \<8 mm as determined by 2D echocardiography(the target region is defined at the time of NOGA® mapping).
6. An LV thrombus.
7. Severe peripheral vascular disease precluding femoral artery access as determined at time of original catheterization.
8. Aortic stenosis as determined as valve area less than 1 cm2 that prohibits catheter access to the LV.
9. Echocardiographic evidence of hypertrophic cardiomyopathy indicating heart muscle thickness \>15 mm.
10. Human immunodeficiency virus (HIV)
11. Serum glucose level ≥ 400 mg/dl within 24 hours of study procedure
12. Serum glucose level 300-400 mg/dl and presence of urine ketones within 24 hours of study procedure.
13. Claustrophobic, or with medical conditions or contradictions that impede performing baseline MRI study.
14. An active uncontrolled infection.
15. A prosthetic aortic valve.
16. Presence of ≥ 20% anti-HLA antibody titers and/or having antibody specificities to donor HLA antigens.
17. A current or prior history within the last 3 years of neoplasm (excluding basal cell) and/or any active neoplasm within the last 24 months.
18. A known hypersensitivity to dimethyl sulfoxide (DMSO), murine and/or bovine products.
19. Pregnancy or breastfeeding.
20. Imprisoned at the time of enrollment.
21. A treatment and/or an uncompleted follow-up treatment of any investigational therapy within 6 months before implantation surgery and intent to participate in any other investigational drug or cell therapy study during the 3-year follow-up period of this study.
22. Active participation in other research therapy for cardiovascular repair/regeneration.
23. A prior recipient of stem precursor cell therapy for cardiac repair.
24. Any medical condition that would affect the investigator's ability to evaluate the subject's condition or could compromise the subject's safety.
25. Any condition that, in the judgment of the investigator, would prohibit the subject from participating in the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Angioblast Systems
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angioblast Systems
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emerson C. Perin, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Texas Heart Institute/St. Luke's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota/Minneapolis Heart Institute
Minneapolis, Minnesota, United States
Texas Heart Institute/St. Luke's Hospital
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EMT-AB001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.